«

»

Rejuvenating Regenerative Medicine Regulation

The Food and Drug Administration (FDA) recently made long-awaited progress toward protecting patients from interventions involving human cell- and tissue-based products (HCT/P) of unknown safety and efficacy. By clarifying its position on the handling and therapeutic use of cells, the agency has…

Read the full post at The New England Journal of Medicine: Search Results in Health Policy and Reform
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive